UC HEALTH LINE: Stress Urine Leaks Can be Stopped With Less Invasive Procedure
Its the first question urogynecologist Mary South, MD, asks patients in order to determine if they experience stress urinary incontinence.
Its easy to diagnose and easy to treat, South says of what can be an embarrassing condition experienced by millions of Americans, more prevalent after childbirth and in older women. Stress urinary incontinence, however, differs from regular incontinence in that loss of urine happens during an episode of exertion such as sneezing, coughing, laughing or exercising.
Stress incontinence falls under the heading of pelvic floor disorders, according to the American Urogynecologic Society (AUGS) and often goes unchecked due to the embarrassment factor. In fact, according to the society, 80 to 90 percent of women who seek help will experience significant improvement.
There is also an outdated element of fear associated with treatment, says South.
In the past, she says, the problem was usually treated with relatively invasive procedures such as a pubovaginal sling or a Burch procedure, which requires an abdominal incision.
We now have minimally invasive slings which only require a 30-minute procedure to place, and most patients are back to work very quickly, says South. No overnight hospitalizations are required. Many patients notice an improvement in symptoms immediately.
South encourages those who answer the cough, sneeze or laugh question with a yes to call and make an appointment to be evaluated as a candidate for the latest sling procedure.
Here, we evaluate women first by history and then a physical exam, she says. We then usually proceed with bladder testing to determine the extent of the problem and if the patient has any other type of urinary incontinence other than stress urinary incontinence.
Tags
Related Stories
Cancer Center plays key role in lab research, clinical trials for new pancreatic cancer drug
September 1, 2026
WLWT and WCPO highlighted the contributions of University of Cincinnati Cancer Center researchers that helped lead to the recent FDA approval of daraxonrasib, a new treatment for pancreatic cancer.
Cancer Center physician receives $150,000 New Investigator Research Grant to study treatment-resistant leukemia
September 1, 2026
The University of Cincinnati Cancer Center’s Sarah Skuli, MD, PhD, received a two‑year, $150,000 Leukemia Research Foundation New Investigator Grant to study TP53‑mutated leukemia, a treatment‑resistant subtype with very poor outcomes.
Heavy social media use linked to depression
August 31, 2026
U.S. News and World Report, Yahoo! News, MSN, USA Today and other national media highlight a new study by the University of Cincinnati and Northwestern University that found a correlation between heavy social media use and depression in adults.